224 related articles for article (PubMed ID: 26635203)
1. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.
Perlman EJ; Gadd S; Arold ST; Radhakrishnan A; Gerhard DS; Jennings L; Huff V; Guidry Auvil JM; Davidsen TM; Dome JS; Meerzaman D; Hsu CH; Nguyen C; Anderson J; Ma Y; Mungall AJ; Moore RA; Marra MA; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Gastier-Foster JM; Ross N; Smith MA
Nat Commun; 2015 Dec; 6():10013. PubMed ID: 26635203
[TBL] [Abstract][Full Text] [Related]
2. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract][Full Text] [Related]
3. Structure and Inhibitor Binding Characterization of Oncogenic MLLT1 Mutants.
Ni X; Londregan AT; Owen DR; Knapp S; Chaikuad A
ACS Chem Biol; 2021 Apr; 16(4):571-578. PubMed ID: 33749253
[TBL] [Abstract][Full Text] [Related]
4. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
5. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
Ramani P; Cowell JK
J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
[TBL] [Abstract][Full Text] [Related]
6. Discovery of an MLLT1/3 YEATS Domain Chemical Probe.
Moustakim M; Christott T; Monteiro OP; Bennett J; Giroud C; Ward J; Rogers CM; Smith P; Panagakou I; Díaz-Sáez L; Felce SL; Gamble V; Gileadi C; Halidi N; Heidenreich D; Chaikuad A; Knapp S; Huber KVM; Farnie G; Heer J; Manevski N; Poda G; Al-Awar R; Dixon DJ; Brennan PE; Fedorov O
Angew Chem Int Ed Engl; 2018 Dec; 57(50):16302-16307. PubMed ID: 30288907
[TBL] [Abstract][Full Text] [Related]
7. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
8. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
9. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
10. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
11. Imprinting, expression, and localisation of DLK1 in Wilms tumours.
Fukuzawa R; Heathcott RW; Morison IM; Reeve AE
J Clin Pathol; 2005 Feb; 58(2):145-50. PubMed ID: 15677533
[TBL] [Abstract][Full Text] [Related]
12. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
13. CITED1 expression in Wilms' tumor and embryonic kidney.
Lovvorn HN; Westrup J; Opperman S; Boyle S; Shi G; Anderson J; Perlman EJ; Perantoni AO; Wills M; de Caestecker M
Neoplasia; 2007 Jul; 9(7):589-600. PubMed ID: 17710162
[TBL] [Abstract][Full Text] [Related]
14. Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.
Raux B; Buchan KA; Bennett J; Christott T; Dowling MS; Farnie G; Fedorov O; Gamble V; Gileadi C; Giroud C; Huber KVM; Korczynska M; Limberakis C; Narayanan A; Owen DR; Sáez LD; Stock IA; Londregan AT
Bioorg Med Chem Lett; 2024 Jan; 98():129546. PubMed ID: 37944866
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
16. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.
Zhou J; Ng Y; Chng WJ
Cell Mol Life Sci; 2018 Nov; 75(21):3931-3941. PubMed ID: 30066088
[TBL] [Abstract][Full Text] [Related]
17. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
18. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel isoform of the leukemia-associated MLLT1 (ENL/LTG19) protein.
Wallingford MC; Filkins R; Adams D; Walentuk M; Salicioni AM; Visconti PE; Mager J
Gene Expr Patterns; 2015 Jan; 17(1):11-5. PubMed ID: 25481096
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of epithelial development and neoplasia in the metanephric kidney.
Davies JA; Perera AD; Walker CL
Int J Dev Biol; 1999; 43(5):473-8. PubMed ID: 10535327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
